Identification

Name
Eplerenone
Accession Number
DB00700  (APRD00707)
Type
Small Molecule
Groups
Approved
Description

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Structure
Thumb
Synonyms
  • Epoxymexrenone
External IDs
SC-66110 / SC-6611O
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EplerenoneTablet, film coated25 mg/1OralAvera Mc Kennan Hospital2015-06-17Not applicableUs
EplerenoneTablet, film coated50 mg/1OralGreenstone, Llc2002-09-27Not applicableUs
EplerenoneTablet, film coated25 mg/1OralGreenstone, Llc2002-09-27Not applicableUs
InspraTablet25 mgOralPfizer2009-05-08Not applicableCanada
InspraTablet, film coated25 mg/1OralG.D. Searle LLC Division of Pfizer Inc2002-09-27Not applicableUs
InspraTablet25 mg/1OralRebel Distributors2002-09-27Not applicableUs
InspraTablet50 mgOralPfizer2009-05-05Not applicableCanada
InspraTablet, film coated50 mg/1OralG.D. Searle LLC Division of Pfizer Inc2002-09-27Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-eplerenoneTablet50 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-eplerenoneTablet25 mgOralApotex CorporationNot applicableNot applicableCanada
EplerenoneTablet50 mg/1OralRebel Distributors2008-08-01Not applicableUs
EplerenoneTablet, film coated25 mg/1OralMylan Pharmaceuticals2017-10-03Not applicableUs
EplerenoneTablet25 mg/1OralAmerincan Health Packaging2015-09-01Not applicableUs
EplerenoneTablet50 mg/1OralEon Labs, Inc.2008-08-01Not applicableUs
EplerenoneTablet50 mg/1OralUpsher Smith Laboratories2015-03-16Not applicableUs
EplerenoneTablet50 mg/1OralApotex Corporation2008-07-30Not applicableUs
EplerenoneTablet, film coated50 mg/1OralMylan Pharmaceuticals2017-10-03Not applicableUs
EplerenoneTablet25 mg/1OralPhysicians Total Care, Inc.2009-09-14Not applicableUs
Categories
UNII
6995V82D0B
CAS number
107724-20-9
Weight
Average: 414.4914
Monoisotopic: 414.204238692
Chemical Formula
C24H30O6
InChI Key
JUKPWJGBANNWMW-VWBFHTRKSA-N
InChI
InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
IUPAC Name
methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0¹,¹⁷.0²,⁷.0¹¹,¹⁵]octadecan]-6'-ene-9'-carboxylate
SMILES

Pharmacology

Indication

For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Structured Indications
Pharmacodynamics

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Mechanism of action

Eplerenone binds to the mineralocorticoid receptor and thereby blocks the binding of aldosterone (component of the renin-angiotensin-aldosterone-system, or RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms.

TargetActionsOrganism
AMineralocorticoid receptor
antagonist
Human
Absorption

The absolute bioavailability of eplerenone is unknown.

Volume of distribution
  • 43 to 90 L
Protein binding

50%

Metabolism

Eplerenone is metabolized primarily by CYP3A4, however, no active metabolites have been identified in human plasma.

Route of elimination
Not Available
Half life

4-6 hours

Clearance
  • Apparent plasma cl=10 L/hr
Toxicity

The most likely symptoms of human overdosage would be anticipated to be hypotension or hyperkalemia. However, no cases of human overdosage with eplerenone have been reported.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Eplerenone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
AcemetacinThe therapeutic efficacy of Eplerenone can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Eplerenone.Approved
AlclofenacAlclofenac may decrease the antihypertensive activities of Eplerenone.Approved, Withdrawn
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Eplerenone.Approved, Illicit
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Eplerenone.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Eplerenone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Eplerenone.Illicit
AmilorideEplerenone may increase the hyperkalemic activities of Amiloride.Approved
AmiodaroneThe serum concentration of Eplerenone can be increased when it is combined with Amiodarone.Approved, Investigational
AndrographolideAndrographolide may decrease the antihypertensive activities of Eplerenone.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Eplerenone.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Eplerenone.Approved
ApocyninApocynin may decrease the antihypertensive activities of Eplerenone.Investigational
ApremilastApremilast may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
AprepitantThe serum concentration of Eplerenone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Eplerenone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Eplerenone can be increased when it is combined with Atomoxetine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Eplerenone.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Eplerenone.Approved
Azilsartan medoxomilEplerenone may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
BenazeprilEplerenone may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Eplerenone.Experimental
BenorilateBenorilate may decrease the antihypertensive activities of Eplerenone.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Eplerenone.Withdrawn
BenzydamineBenzydamine may decrease the antihypertensive activities of Eplerenone.Approved
BevoniumBevonium may decrease the antihypertensive activities of Eplerenone.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Eplerenone.Experimental, Illicit, Withdrawn
BoceprevirThe serum concentration of Eplerenone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Eplerenone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Eplerenone can be decreased when it is combined with Bosentan.Approved, Investigational
BrigatinibThe serum concentration of Eplerenone can be decreased when it is combined with Brigatinib.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Eplerenone.Approved
BucillamineBucillamine may decrease the antihypertensive activities of Eplerenone.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Eplerenone.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Eplerenone.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Eplerenone.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Eplerenone.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Eplerenone.Approved
CandesartanEplerenone may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Eplerenone.Approved
CandoxatrilEplerenone may increase the hyperkalemic activities of Candoxatril.Experimental
CaptoprilEplerenone may increase the hyperkalemic activities of Captopril.Approved
CarbamazepineThe metabolism of Eplerenone can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Eplerenone.Experimental, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Eplerenone.Illicit, Investigational, Vet Approved
CarprofenCarprofen may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the antihypertensive activities of Eplerenone.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
CeritinibThe serum concentration of Eplerenone can be increased when it is combined with Ceritinib.Approved
ChloroquineChloroquine may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Eplerenone.Approved
CilazaprilEplerenone may increase the hyperkalemic activities of Cilazapril.Approved
ClarithromycinThe serum concentration of Eplerenone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Eplerenone can be increased when it is combined with Clemastine.Approved
ClonixinClonixin may decrease the antihypertensive activities of Eplerenone.Approved
ClotrimazoleThe serum concentration of Eplerenone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Eplerenone can be increased when it is combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Eplerenone.Approved, Illicit
ConivaptanThe serum concentration of Eplerenone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Eplerenone can be increased when it is combined with Crizotinib.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Eplerenone.Investigational
CyclosporineEplerenone may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Eplerenone can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Eplerenone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Eplerenone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Eplerenone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilEplerenone may increase the hyperkalemic activities of Delapril.Experimental
DelavirdineThe serum concentration of Eplerenone can be increased when it is combined with Delavirdine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Eplerenone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Eplerenone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Eplerenone.Approved, Investigational
DiclofenacDiclofenac may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Eplerenone.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Eplerenone.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Eplerenone.Approved, Illicit
DihydroergotamineThe serum concentration of Eplerenone can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Eplerenone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Eplerenone.Experimental, Illicit
DiltiazemThe serum concentration of Eplerenone can be increased when it is combined with Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Eplerenone.Approved, Illicit
DoxycyclineThe serum concentration of Eplerenone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Eplerenone.Experimental
DronedaroneThe serum concentration of Eplerenone can be increased when it is combined with Dronedarone.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Eplerenone.Withdrawn
DuvelisibDuvelisib may decrease the antihypertensive activities of Eplerenone.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Eplerenone.Investigational
EnalaprilEplerenone may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatEplerenone may increase the hyperkalemic activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Eplerenone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Eplerenone.Approved
EprosartanEplerenone may increase the hyperkalemic activities of Eprosartan.Approved
ErythromycinThe serum concentration of Eplerenone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Eplerenone.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Eplerenone.Approved, Illicit
EtodolacEtodolac may decrease the antihypertensive activities of Eplerenone.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Eplerenone.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Eplerenone.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Eplerenone.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Eplerenone.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Eplerenone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Eplerenone.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Eplerenone.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Eplerenone.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Eplerenone.Experimental
FimasartanEplerenone may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FloctafenineFloctafenine may decrease the antihypertensive activities of Eplerenone.Approved, Withdrawn
FluconazoleThe serum concentration of Eplerenone can be increased when it is combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Eplerenone.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Eplerenone.Experimental
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
FluvoxamineThe serum concentration of Eplerenone can be increased when it is combined with Fluvoxamine.Approved, Investigational
ForasartanEplerenone may increase the hyperkalemic activities of Forasartan.Experimental
FosamprenavirThe serum concentration of Eplerenone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Eplerenone can be increased when it is combined with Fosaprepitant.Approved
FosinoprilEplerenone may increase the hyperkalemic activities of Fosinopril.Approved
FosphenytoinThe metabolism of Eplerenone can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Eplerenone can be increased when it is combined with Fusidic Acid.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Eplerenone.Experimental
HeparinHeparin may increase the hyperkalemic activities of Eplerenone.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Eplerenone.Approved, Illicit, Investigational
HigenamineHigenamine may decrease the antihypertensive activities of Eplerenone.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Eplerenone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Eplerenone.Approved, Illicit
IbuprofenIbuprofen may decrease the antihypertensive activities of Eplerenone.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Eplerenone.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Eplerenone.Approved
IdelalisibThe serum concentration of Eplerenone can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Eplerenone can be increased when it is combined with Imatinib.Approved
ImidaprilEplerenone may increase the hyperkalemic activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Eplerenone.Experimental
IndinavirThe serum concentration of Eplerenone can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Eplerenone.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Eplerenone.Withdrawn
IrbesartanEplerenone may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Eplerenone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may decrease the antihypertensive activities of Eplerenone.Withdrawn
IsradipineThe serum concentration of Eplerenone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Eplerenone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Eplerenone can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Eplerenone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Eplerenone.Approved, Investigational
KetoconazoleThe serum concentration of Eplerenone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Eplerenone.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Eplerenone.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Eplerenone.Approved
LisinoprilEplerenone may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Eplerenone.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Eplerenone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Eplerenone.Illicit
LonazolacLonazolac may decrease the antihypertensive activities of Eplerenone.Experimental
LopinavirThe serum concentration of Eplerenone can be increased when it is combined with Lopinavir.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
LorpiprazoleThe serum concentration of Eplerenone can be increased when it is combined with Lorpiprazole.Approved
LosartanEplerenone may increase the hyperkalemic activities of Losartan.Approved
LovastatinThe serum concentration of Eplerenone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
LuliconazoleThe serum concentration of Eplerenone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Eplerenone can be increased when combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Eplerenone.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Eplerenone.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Eplerenone.Experimental
MesalazineMesalazine may decrease the antihypertensive activities of Eplerenone.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Eplerenone.Investigational, Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Eplerenone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Eplerenone.Approved, Illicit
MifepristoneThe serum concentration of Eplerenone can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Eplerenone can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Eplerenone.Investigational
MoexiprilEplerenone may increase the hyperkalemic activities of Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Eplerenone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Eplerenone.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Eplerenone.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Eplerenone.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Eplerenone.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Eplerenone.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
NefazodoneThe serum concentration of Eplerenone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Eplerenone can be increased when it is combined with Nelfinavir.Approved
NepafenacNepafenac may decrease the antihypertensive activities of Eplerenone.Approved
NetupitantThe serum concentration of Eplerenone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Eplerenone can be increased when it is combined with Nevirapine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Eplerenone.Experimental
NifenazoneNifenazone may decrease the antihypertensive activities of Eplerenone.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Eplerenone.Approved
NilotinibThe serum concentration of Eplerenone can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Eplerenone.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Eplerenone.Investigational
NitrofurantoinNitrofurantoin may increase the hyperkalemic activities of Eplerenone.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Eplerenone.Approved, Illicit
OlaparibThe serum concentration of Eplerenone can be increased when it is combined with Olaparib.Approved
OlmesartanEplerenone may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Eplerenone.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Eplerenone.Approved
OmapatrilatEplerenone may increase the hyperkalemic activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Eplerenone.Approved, Illicit
OrgoteinOrgotein may decrease the antihypertensive activities of Eplerenone.Vet Approved
OsimertinibThe serum concentration of Eplerenone can be increased when it is combined with Osimertinib.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Eplerenone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eplerenone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Eplerenone.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Eplerenone.Approved, Withdrawn
PalbociclibThe serum concentration of Eplerenone can be increased when it is combined with Palbociclib.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Eplerenone.Approved
ParthenolideParthenolide may decrease the antihypertensive activities of Eplerenone.Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Eplerenone.Approved, Vet Approved
PentobarbitalThe metabolism of Eplerenone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilEplerenone may increase the hyperkalemic activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Eplerenone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Eplerenone.Experimental
PhenobarbitalThe metabolism of Eplerenone can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Eplerenone.Experimental
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
PhenytoinThe metabolism of Eplerenone can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Eplerenone.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Eplerenone.Experimental
PosaconazoleThe serum concentration of Eplerenone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Eplerenone.Experimental, Investigational
PrimidoneThe metabolism of Eplerenone can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Eplerenone.Experimental
PropacetamolPropacetamol may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Eplerenone.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Eplerenone.Experimental
PTC299PTC299 may decrease the antihypertensive activities of Eplerenone.Investigational
QuinaprilEplerenone may increase the hyperkalemic activities of Quinapril.Approved, Investigational
RamiprilEplerenone may increase the hyperkalemic activities of Ramipril.Approved
RanolazineThe serum concentration of Eplerenone can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Eplerenone.Approved
RescinnamineEplerenone may increase the hyperkalemic activities of Rescinnamine.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Eplerenone.Approved, Experimental, Investigational
RibociclibThe serum concentration of Eplerenone can be increased when it is combined with Ribociclib.Approved
RifabutinThe metabolism of Eplerenone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Eplerenone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Eplerenone can be increased when combined with Rifapentine.Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Eplerenone.Investigational, Withdrawn
RucaparibThe serum concentration of Eplerenone can be increased when it is combined with Rucaparib.Approved, Investigational
SacubitrilEplerenone may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Eplerenone.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Eplerenone.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Eplerenone.Approved
SaprisartanEplerenone may increase the hyperkalemic activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Eplerenone can be increased when it is combined with Saquinavir.Approved, Investigational
SaralasinEplerenone may increase the hyperkalemic activities of Saralasin.Investigational
SarilumabThe therapeutic efficacy of Eplerenone can be decreased when used in combination with Sarilumab.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Eplerenone.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Eplerenone.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Eplerenone.Investigational
SildenafilThe serum concentration of Eplerenone can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Eplerenone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Eplerenone can be increased when it is combined with Simeprevir.Approved
Sodium phosphateEplerenone may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilEplerenone may increase the hyperkalemic activities of Spirapril.Approved
SRT501SRT501 may decrease the antihypertensive activities of Eplerenone.Investigational
St. John's WortThe serum concentration of Eplerenone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Eplerenone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Eplerenone.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Eplerenone.Approved
SulfisoxazoleThe serum concentration of Eplerenone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Eplerenone.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Eplerenone.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Eplerenone.Experimental
TacrolimusEplerenone may increase the hyperkalemic activities of Tacrolimus.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Eplerenone.Approved
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Eplerenone.Investigational
TasosartanEplerenone may increase the hyperkalemic activities of Tasosartan.Approved
TelaprevirThe serum concentration of Eplerenone can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Eplerenone can be increased when it is combined with Telithromycin.Approved
TelmisartanEplerenone may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemocaprilEplerenone may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Eplerenone.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Eplerenone.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Eplerenone.Vet Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Eplerenone.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Eplerenone.Approved
TiclopidineThe serum concentration of Eplerenone can be increased when it is combined with Ticlopidine.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Eplerenone.Experimental
TinoridineTinoridine may decrease the antihypertensive activities of Eplerenone.Investigational
TocilizumabThe serum concentration of Eplerenone can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Eplerenone.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Eplerenone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Eplerenone.Approved, Investigational
TrandolaprilEplerenone may increase the hyperkalemic activities of Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
TriamtereneEplerenone may increase the hyperkalemic activities of Triamterene.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Eplerenone.Experimental
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Eplerenone.Approved, Vet Approved
TriptolideTriptolide may decrease the antihypertensive activities of Eplerenone.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Eplerenone.Investigational, Withdrawn
ValsartanEplerenone may increase the hyperkalemic activities of Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Eplerenone can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Eplerenone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Eplerenone can be increased when it is combined with Verapamil.Approved
VoriconazoleThe serum concentration of Eplerenone can be increased when it is combined with Voriconazole.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Eplerenone.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Eplerenone.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Eplerenone can be increased when it is combined with Ziprasidone.Approved
ZofenoprilEplerenone may increase the hyperkalemic activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Eplerenone.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Bhaskar Reddy Guntoori, Svetoslav S. Bratovanov, Mohamed Ibrahim Zaki, Elena Bejan, Stephen E. Horne, "Process for the preparation and purification of eplerenone." U.S. Patent US20080234478, issued September 25, 2008.

US20080234478
General References
Not Available
External Links
Human Metabolome Database
HMDB0014838
KEGG Drug
D01115
KEGG Compound
C12512
PubChem Compound
443872
PubChem Substance
46509053
ChemSpider
10203511
BindingDB
50318300
ChEBI
31547
ChEMBL
CHEMBL1095097
Therapeutic Targets Database
DAP000085
PharmGKB
PA164749044
IUPHAR
2876
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Eplerenone
ATC Codes
C03DA04 — Eplerenone
AHFS Codes
  • 24:32.20 — Mineralocorticoid (Aldosterone) Receptor Antagonists
FDA label
Download (136 KB)
MSDS
Download (68.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableChronic Kidney Disease (CKD)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePharmacology, Clinical1
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1Not Yet RecruitingNot AvailableFasting / Healthy Volunteers / Pharmacokinetics1
1Not Yet RecruitingScreeningType 2 Diabetes Mellitus1
1RecruitingNot AvailableHealthy Volunteers1
1RecruitingTreatmentDiabetic Nephropathies1
1WithdrawnOtherHealthy Volunteers1
1, 2CompletedTreatmentGitelman's syndrome1
1, 2RecruitingTreatmentCKD II-III1
2Active Not RecruitingTreatmentCentral Serous Chorioretinopathy (CSC)1
2CompletedTreatmentChronic Kidney Disease (CKD)1
2CompletedTreatmentDiabetic Nephropathies1
2CompletedTreatmentHeart Failure, Unspecified2
2CompletedTreatmentHigh Blood Pressure (Hypertension)1
2CompletedTreatmentHypertension,Essential2
2TerminatedPreventionNonvalvular Atrial Fibrillation1
2TerminatedTreatmentCardiac Steatosis / Hepatic Steatosis1
2TerminatedTreatmentHigh Blood Pressure (Hypertension)2
2Unknown StatusTreatmentCentral Serous Chorioretinopathy (CSC)1
2Unknown StatusTreatmentChronic Kidney Insufficiency / Transplantation, Kidney1
2WithdrawnTreatmentAscites / Liver Cirrhosis1
2, 3Not Yet RecruitingTreatmentCentral Serous Chorioretinopathy (CSC)1
2, 3RecruitingTreatmentPrimary Hyperparathyroidism1
2, 3TerminatedPreventionCancer, Breast1
3Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
3Active Not RecruitingTreatmentGlucose tolerance impaired / Heart Failure, Unspecified / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentHypertension,Essential1
3CompletedPreventionEndothelial Dysfunction / Metabolic Syndromes1
3CompletedTreatmentHeart Failure, Unspecified2
3CompletedTreatmentHigh Blood Pressure (Hypertension)2
3CompletedTreatmentHypertension,Essential1
3RecruitingTreatmentPhospholamban R14del Mutation-related Cardiomyopathy1
3TerminatedTreatmentChronic Kidney Disease (CKD)1
4Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
4CompletedBasic SciencePharmacodynamics1
4CompletedPreventionHigh Blood Pressure (Hypertension)1
4CompletedPreventionKidney Failure,Chronic1
4CompletedPreventionMyocardial Infarction (MI)1
4CompletedTreatmentAtrial Switch Procedure / Transposition of the Great Vessels / Transposition of the Great Vessels With Atrial Switch1
4CompletedTreatmentChronic Central Serous Chorioretinopathy1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentCongestive Heart Failure (CHF) / Diastole1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentIschaemic Heart Diseases1
4CompletedTreatmentMyocardial Infarction (MI)1
4RecruitingBasic ScienceAbdominal Obesity Metabolic Syndrome / High Blood Pressure (Hypertension) / Insulin Resistance1
4RecruitingTreatmentAortic Aneurysm, Abdominal1
4RecruitingTreatmentChronic Central Serous Chorioretinopathy1
4TerminatedPreventionMetabolic Syndromes1
4TerminatedTreatmentDiastolic Heart Failure1
4TerminatedTreatmentSingle Ventricle With a Fontan Palliation / Tetralogy Of Fallot / Transposition of the Great Vessels With an Arterial Switch1
4Unknown StatusDiagnosticDialysis therapy / High Blood Pressure (Hypertension) / Hyperaldosteronism1
4Unknown StatusSupportive CareMetabolic Syndromes1
4Unknown StatusTreatmentHypertensive Left Ventricular Hypertrophy1
4Unknown StatusTreatmentProphylaxis of cardiomyopathy1
4WithdrawnTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension)1
4WithdrawnTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableActive Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedBasic ScienceHypoglycemia1
Not AvailableCompletedPreventionSystemic Proinflammatory State1
Not AvailableCompletedTreatmentAlbuminuria / Diabetes Mellitus (DM) / Endothelial Dysfunction1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentCentral Serous Chorioretinopathy (CSC)1
Not AvailableCompletedTreatmentDiastolic Heart Failure1
Not AvailableCompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
Not AvailableCompletedTreatmentEnd Stage Renal Disease (ESRD) / Hemodialysis-dependent patients1
Not AvailableCompletedTreatmentIschemia-Reperfusion Injury1
Not AvailableRecruitingNot AvailableChronic Heart Failure (CHF)1
Not AvailableRecruitingBasic ScienceEndothelial Dysfunction / Insulin Resistance1
Not AvailableRecruitingBasic SciencePrimary Aldosteronism1
Not AvailableRecruitingDiagnosticHigh Blood Pressure (Hypertension)1
Not AvailableRecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
Not AvailableTerminatedPreventionMyocardial Remodeling1
Not AvailableUnknown StatusPreventionHypoglycemia1
Not AvailableUnknown StatusScreeningHigh Blood Pressure (Hypertension) / Hyperaldosteronism1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Sandoz inc
  • Gd searle llc
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
TabletOral25 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Inspra 25 mg tablet4.87USD tablet
Inspra 50 mg tablet4.87USD tablet
Eplerenone 25 mg tablet4.18USD tablet
Eplerenone 50 mg tablet4.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6863902No2000-10-102020-10-10Us
US6410054Yes2000-06-082020-06-08Us
US6410524Yes2000-05-052020-05-05Us
US6495165Yes2000-06-082020-06-08Us
US6534093Yes2000-06-082020-06-08Us
US6558707Yes2000-06-082020-06-08Us
US6747020Yes2000-05-052020-05-05Us
US7157101Yes2000-06-082020-06-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00903 mg/mLALOGPS
logP1.67ALOGPS
logP2.33ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)15.11ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area82.2 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity106.68 m3·mol-1ChemAxon
Polarizability43.79 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9839
Blood Brain Barrier+0.8556
Caco-2 permeable+0.5076
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor IInhibitor0.8166
P-glycoprotein inhibitor IIInhibitor0.8066
Renal organic cation transporterNon-inhibitor0.7209
CYP450 2C9 substrateNon-substrate0.8229
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.6978
CYP450 2C9 inhibitorNon-inhibitor0.7982
CYP450 2D6 inhibitorNon-inhibitor0.931
CYP450 2C19 inhibitorNon-inhibitor0.839
CYP450 3A4 inhibitorNon-inhibitor0.8368
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8902
Ames testNon AMES toxic0.7496
CarcinogenicityNon-carcinogens0.9441
BiodegradationNot ready biodegradable0.9891
Rat acute toxicity2.4761 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9453
hERG inhibition (predictor II)Non-inhibitor0.7742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Spironolactones and derivatives
Alternative Parents
Oxepanes / Cyclohexenones / Gamma butyrolactones / Dicarboxylic acids and derivatives / Tetrahydrofurans / Methyl esters / Oxacyclic compounds / Epoxides / Dialkyl ethers / Organic oxides
show 1 more
Substituents
Spironolactone / Cyclohexenone / Oxepane / Dicarboxylic acid or derivatives / Gamma butyrolactone / Tetrahydrofuran / Methyl ester / Carboxylic acid ester / Ketone / Lactone
show 13 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
3-oxo steroid, epoxide, methyl ester, gamma-lactone, oxaspiro compound, steroid acid ester (CHEBI:31547)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Moore TD, Nawarskas JJ, Anderson JR: Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003 Sep-Oct;5(5):354-63. [PubMed:14503934]
  2. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003 Nov 5;42(9):1666-73. [PubMed:14607457]
  3. Rogerson FM, Yao Y, Smith BJ, Fuller PJ: Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Pharmacol Physiol. 2004 Oct;31(10):704-9. [PubMed:15554912]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2018 10:50